Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Naoki Ikenaga

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-6285-6883; OpenAlex author ID A5051237437, A5133488242. Sources: OpenAlex.

Their work

Papers
43 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
130
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 5 papers · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: 3 papers · 2023: 8 papers · 2024: 8 papers · 2025: 5 papers · 2026: 5 papers

Papers 43

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… First author DOI 10.1002/ags3.70090↗
  2. Positioning serum autoantibody signatures within the evolving landscape of early pancreatic cancer detection. Co-author DOI 10.1016/j.pan.2025.12.016↗
  3. S100A6 expression in resected specimens predicts lymph node metastasis in small pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.surg.2026.110423↗
  4. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  5. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  6. Efficacy and Safety of Surgical Treatment Among Older Adult Patients (80 Years) With Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1002/jhbp.12151↗
  7. Identification of cold tumor induction-related markers in pancreatic cancer and the clinical implication of PCDH7. Co-author DOI 10.1007/s00432-025-06095-z↗
  8. Clinical efficacy of pancreas-preserving distal pancreatectomy for the treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.108958↗
  9. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29823-4↗
  10. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Co-author DOI 10.3389/fimmu.2025.1571182↗
  11. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/deo2.333↗
  12. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  13. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-1004↗
  14. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  15. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. Co-author DOI 10.1186/s13046-024-03060-5↗
  16. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13046-024-03178-6↗
  17. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03192-8↗
  18. [Microbiome in the Therapy for the Pancreatic Cancer]. Co-author PMID 39009514↗
  19. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  20. Minimally invasive distal pancreatectomy for pancreatic cancer: cranial-to-caudal approach with identification of Gerota's fascia (with video). Co-author DOI 10.1007/s00464-023-10438-7↗
  21. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  22. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-023-05591-2↗
  23. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. First author DOI 10.1111/cas.15901↗
  24. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  25. ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement. Co-author DOI 10.1245/s10434-022-12584-z↗
  26. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection. Co-author DOI 10.1245/s10434-023-13936-z↗
  27. Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compa… Co-author DOI 10.1007/s00423-022-02453-4↗
  28. Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s12672-021-00462-1↗
  29. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  30. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Co-author DOI 10.1007/s00595-020-02123-2↗
  31. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2021.04.013↗
  32. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Co-author DOI 10.1016/j.pan.2021.04.002↗
  33. Efficient pre-treatment for pancreatic cancer using chloroquine-loaded nanoparticles targeting pancreatic stellate cells. Co-author DOI 10.3892/ol.2021.12894↗
  34. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. First author DOI 10.1097/mpa.0000000000000092↗
  35. Peritoneal myofibroblasts at metastatic foci promote dissemination of pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2391↗
  36. MAL2 expression predicts distant metastasis and short survival in pancreatic cancer. Co-author DOI 10.1016/j.surg.2013.03.010↗
  37. Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e318279bd66↗
  38. Migratory activity of CD105+ pancreatic cancer cells is strongly enhanced by pancreatic stellate cells. Co-author DOI 10.1097/mpa.0b013e318293e7bd↗
  39. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Co-author DOI 10.1158/0008-5472.can-12-3180↗
  40. Kindlin-1 expression is involved in migration and invasion of pancreatic cancer. Co-author DOI 10.3892/ijo.2013.1838↗
  41. Pancreatic cancer cells enhance the ability of collagen internalization during epithelial-mesenchymal transition. Co-author DOI 10.1371/journal.pone.0040434↗
  42. CD271⁺ subpopulation of pancreatic stellate cells correlates with prognosis of pancreatic cancer and is regulated by interaction with cancer cells. Co-author DOI 10.1371/journal.pone.0052682↗
  43. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Co-author DOI 10.1016/j.surg.2011.06.017↗

Closest collaborators

The 25 strongest of 130 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 27 shared papers, 2011–2026 · strength 4.44
  2. Kenoki Ohuchida · 28 shared papers, 2011–2026 · strength 3.38
  3. Toshiya Abe · 15 shared papers, 2022–2026 · strength 2.64
  4. Masafumi Nakamura · 16 shared papers, 2021–2026 · strength 2.52
  5. Noboru Ideno · 13 shared papers, 2022–2026 · strength 2.30
  6. Chika Iwamoto · 13 shared papers, 2021–2025 · strength 2.18
  7. Yoshinao Oda · 14 shared papers, 2011–2026 · strength 2.15
  8. Takao Ohtsuka · 15 shared papers, 2012–2026 · strength 2.02
  9. Masafumi Nakamura · 8 shared papers, 2022–2025 · strength 1.67
  10. Koki Oyama · 7 shared papers, 2023–2025 · strength 1.22
  11. Koji Shindo · 12 shared papers, 2012–2024 · strength 1.18
  12. Kousei Ishigami · 6 shared papers, 2022–2026 · strength 1.04
  13. Masataka Hayashi · 6 shared papers, 2023–2024 · strength 1.03
  14. Tomohiko Shinkawa · 6 shared papers, 2021–2025 · strength 0.95
  15. Chikanori Tsutsumi · 5 shared papers, 2024–2025 · strength 0.92
  16. Hideya Onishi · 4 shared papers, 2024–2026 · strength 0.81
  17. Pingshan Zhong · 5 shared papers, 2021–2024 · strength 0.75
  18. Nao Fujimori · 4 shared papers, 2022–2025 · strength 0.71
  19. So Nakamura · 4 shared papers, 2023–2024 · strength 0.69
  20. Yuki Mochida · 4 shared papers, 2022–2025 · strength 0.68
  21. Haizhen Luo · 4 shared papers, 2023–2024 · strength 0.63
  22. Nobuhiro Fujita · 3 shared papers, 2023–2025 · strength 0.57
  23. Masafumi Nakamura · 3 shared papers, 2023–2025 · strength 0.57
  24. Bo Zhang · 3 shared papers, 2023–2025 · strength 0.55
  25. Shintaro Yagi · 3 shared papers, 2024–2026 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.